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http://dx.doi.org/10.1016/j.jfma.201Hyperthyroidism is an important inducing factor in patients with atrial fibrillation, and may
trigger heart failure. Thyrotropin (thyroid stimulating hormone, TSH)-secreting pituitary
tumors are rare causes of hyperthyroidism. Here, we report a 66-year-old man with a pituitary
TSH-secreting tumor who presented with hyperthyroidism and congestive heart failure. Endo-
nasal trans-sphenoidal pituitary adenomectomy was performed. After the operation, the
symptoms of hyperthyroidism and congestive heart failure were relieved, associated with
normalization of thyroid function tests. Unfortunately, hand tremor and progressively elevated
free T4 and TSH concentrations recurred 5 months after surgery. A dopaminergic agonist,
cabergoline was administered and euthyroidism was restored for at least 11 months.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Heart failure1 is a major public health problem in Taiwan
that continues to grow, with a recent prevalence rate of
about 5% in the Taiwanese population.2 The association andnt of Internal Medicine,
o. 7 Chung-Shan South Road,
tw (T.-S. Huang).
qually.
ight ª 2012, Elsevier Taiwan LLC
2.07.015complex interaction between atrial fibrillation (AF) and
heart failure is well understood.3 Etiologies of AF include
hypertension, ischemic heart disease, and hyperthyroidism.
As a reversible cause of AF-induced heart failure, checking
thyroid function to exclude hyperthyroidism is important in
the assessment of patients with AF.4
The prevalence rate of hyperthyroidism varies from 0.5
to 2.3%.5,6 In the elderly group, the prevalence rate
increases to 6.98%, based on a recent survey in Taiwan.7
The most common cause is Graves’ disease, an autoim-
mune disease caused by stimulating antibodies directed& Formosan Medical Association. All rights reserved.
722 Y.-H. Kao et al.against the thyroid stimulating hormone (TSH) receptor.8
However, other rare conditions including TSH-secreting
tumors also cause hyperthyroidism.
Initially described in 1960 by Jailer and Holub,9 TSH-
secreting pituitary tumors are found to account for about
1% of the functioning pituitary tumors and for <1% of all the
causes of hyperthyroidism.10 Patients usually present with
goiter and hyperthyroidism, along with inappropriately
normal or elevated TSH concentrations.11 Such cases are
easily misdiagnosed as Graves’ disease, despite the fact
that the treatment modality is totally different. First-line
therapy of patients with TSH-secreting pituitary tumors is
trans-sphenoidal resection of the tumor by which about
one-third of all patients can be cured completely.10
However, if surgery is contraindicated, pituitary radio-
therapy and/or administration of somatostatin analogs or
dopaminergic agonists should be considered.12,13
Here, we report a Taiwanese patient with pituitary
microadenoma-induced goiter and hyperthyroidism. The
pathology of pituitary tumor confirmed the diagnosis of
TSH-secreting pituitary tumor. The symptoms and signs
were relieved after trans-sphenoidal pituitary adenomec-
tomy. However, recurrent hyperthyroidism occurred
without obvious tumor regrowth in the pituitary glandFigure 1 (A) Thyroid echo showed multinodular goiter without
weighted magnetic resonance imaging with contrast of pituitary
pituitary microadenoma. (C) Pathology of the pituitary adenoma sh
nucleus (hematoxylin and eosin, 400). (D) Immunohistochemicalbased on magnetic resonance image (MRI) studies. Dopa-
minergic agonist was administered, the symptoms and signs
were relieved and biochemical euthyroidism was restored
for at least 11 months.Case report
A 66-year-old man had a history of hypertension for 10
years, type 2 diabetes mellitus for 1 year, and atrial
fibrillation for 1 year. Goiter was incidentally found, asso-
ciated with elevated serum freeT4 and TSH levels in 2007 at
a local hospital. None of his family had thyroid or other
endocrine disorders. He suffered from dizziness, palpita-
tion, and exertional dyspnea for 2 days, followed by sudden
onset syncope on March 10, 2008. He was then sent to the
emergency department of National Taiwan University
Hospital. Noncontrast brain computed tomography and MRI
did not show evidence of recent intracranial hemorrhage or
ischemic stroke. Electrocardiography revealed atrial fibril-
lation with rapid ventricular response (heart rate 190/min).
Chest plain film revealed cardiomegaly with bilateral
pleural effusion and enlargement of bilateral hilar regions.
Cardiac ultrasonography on March 11 revealed severeobvious autoimmune thyroid disease pattern. (B) Coronal T1-
gland before operation (March 10, 2008) showed one 8 mm
owed hypervascularity without fibrosis, mitosis, or polymorphic
stain for TSH was positive in the cytoplasm. (TSH stain, 400).
Figure 2 Coronal T1-weighted magnetic resonance imaging
with contrast of pituitary gland after operation (October 16,
2008) showed cystic change without evidence of local recur-
rence of pituitary adenoma.
TSH-secreting pituitary tumor response to cabergoline 723tricuspid valve regurgitation, and poor left ventricular
contractility (left ventricular ejection fraction 38%). Under
the impression of congestive heart failure, possibly related
to atrial fibrillation with rapid ventricular rate, oral
propranolol 20 mg three times a day, intravenous furose-
mide 5 mg every 12 hours were administered, and intrave-
nous digitalization 0.25 mg every 12 hours was given. Oral
propylthiouracil 100 mg three times a day, and oral diluted
Lugol’s solution 10 ml three times a day were administered
for thyrotoxicosis. The heart rate decreased gradually with
the use of propylthiouracil, propranolol, and diluted Lugol’s
solution. Rashes developed over the chest wall on March 19,
propylthiouracil was discontinued under the suspicion of
drug allergy, and oral lithium 300 mg twice a day was
administered. Secondary hyperthyroidism was suspected
due to the concurrent elevation of free T4 (4.31 ng/dL) and
TSH levels (4.79 mIU/mL). Additionally, thyroid echo
showed multinodular goiter and isoechogenicity different
from diffuse reduction in thyroid echogenicity (low-ampli-
tude echoes) which often presents in autoimmune thyroid
disease (Fig. 1A).14 The absence of thyroid binding inhibi-
tory immunoglobulins (TBII, TSH receptor antibody) and
thyroglobulin antibody also favored a non-autoimmune
thyroid disorder. Pituitary MRI revealed an 8 mm pituitary
microadenoma in the left lobe (Fig. 1B). Other pituitary
hormone concentrations were within normal limits (8AM
cortisol, 13.4 mg/dL; 8AM adrenocorticotropic hormone,
47.2 pg/mL; follicle stimulating hormone, 4.84 mIU/mL;
lutenizing hormone, 5.99 mIU/mL; estradiol, 37.7 pg/mL;
testosterone, 5.12 ng/mL; prolactin, 4.25 pg/mL; growth
hormone, 4.24 ng/mL). Therefore, TSH-secreting pituitary
microadenoma was highly suspected. Trans-sphenoid pitu-
itary adenomectomy was performed on April 5, 2008.
Pathology showed an 8 mm hypervascular adenoma without
fibrosis, mitosis, or polymorphic nucleus (Fig. 1C). Immu-
nohistochemical stain was positive for TSH in the cytoplasm
(Fig. 1D). TSH (0.20 mIU/mL) and freeT4 (1.38 ng/dL) levels
declined to normal after adenomectomy. However, hand
tremor recurred and serial follow-ups of TSH and freeT4
suggested the recurrence of TSH-secreting pituitary
adenoma (Fig. 2). Pituitary MRI on October 16, 2009 failed
to locate the pituitary adenoma (Fig. 2). Therefore, oper-
ation or radiation therapy was not feasible. A 2.5 mg
bromocriptine suppression test was performed, and the TSH
was suppressed to 60% of basal level (initial, 0.615 mIU/mL;
6 hours after suppression, 0.37 mIU/mL; Table 1). As
a result, a dopaminergic agonist, cabergoline 1 mg once/
week was prescribed from December 3, 2008. The serum
TSH and free T4 levels decreased gradually, and euthyroid
status (free T4: 1.10 ng/dL, TSH: 0.96 mIU/mL) had been
restored for at least 11 months at the time of writing
(Fig. 3).Table 1 Bromocriptine test. Baseline free T4 2.36 ng/dL,
TSH 0.615 mIU/mL.
0 1 h 3 h 6 h 24 h
PRL (pg/ml) 5.55 3.27 1.16 0.74 0.72
GH (ng/ml) 0.103 0.172 1.63 1.47 0.099
TSH (mIU/ml) 0.615 0.514 0.395 0.370 0.417Discussion
We report a pathologically proven case of TSH-secreting
pituitary tumor presented with atrial fibrillation and heart
failure that had been initially misdiagnosed as Graves’
disease. A correct diagnosiswasmadebased on the laboratory
findings of elevated free T4 associated with inappropriately
elevated TSH, and a pituitary tumor detected by MRI.Once misdiagnosed as Graves’ disease, thyroidectomy
performed in patients with pituitary TSH secreting tumors
may cause serious aggressive transformation of the pitui-
tary tumors. Similar mechanisms that lead to aggressive
transformation of pituitary tumor after adrenalectomy in
Nelson’s syndrome also exist in patients with TSH-secreting
pituitary tumors receiving thyroid ablation.13 To avoid
unfavorable consequences in the management of TSH-
secreting pituitary tumors, thyroid hormone levels should
be kept at upper limits of normal range to prevent an
additional stimulus to the pituitary tumor.15
For the initial management of thyrotoxicosis-induced
atrial fibrillation and heart failure, and the prevention of
operation-related thyroid storm,16 we used propylthiour-
acil, b-adrenergic blocking agents, diuretics, and diluted
Lugol solution. For definitive treatment, surgical adeno-
mectomy may be required to cure TSH-secreting pituitary
tumors. The criteria of cure are based on the establishment
of biochemical and clinical euthyroidism, as well as on
pituitary imaging studies.17 The surgical outcome of total
resection ranges from 76.7% to 88% according to different
tumor sizes.18,19 Nevertheless, when a surgical approach is
contraindicated or incomplete resection occurs such as in
Figure 3 Chronological changes in serum TSH and free T4
levels related to operation and cabergoline treatment. The
blue line <> indicates the upper limit of serum TSH level, and
the purple line [] indicates the upper limit of serum free T4
level.
724 Y.-H. Kao et al.our case, conservative treatment, including radiotherapy
and/or administration of somatostatin/dopaminergic
agonists, should be considered to normalize the circulating
thyroid hormone levels and stabilize or even reduce the
tumor sizes.
The use of somatostatin analog for TSH-secreting pitui-
tary tumors is effective in reducing tumor size and restoring
euthyroid state in >90% of patients. Although administra-
tion of dopaminergic agonist may not cause tumor
shrinkage in those without combined hypersecretion of TSH
and PRL,20 some patients showed good responses evident by
normalization of thyroid functions.21 Because of the high
costs of somatostatin analog and the potential side effects
of hyperglycemia related to somatostatin analog, we used
a dopaminergic agonist to treat our patient. We observed
a good response to cabergoline in this patient in the 11
months of follow-up. Long-term multi-modality follow-up
including clinical, biochemical, and radiological examina-
tions is warranted to keep the patient in euthyroid state.
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